Seroprevalence and burden of hepatitis C virus infection in WHO South-East Asia Region: A systematic review
- PMID: 35263807
- DOI: 10.1111/jgh.15827
Seroprevalence and burden of hepatitis C virus infection in WHO South-East Asia Region: A systematic review
Abstract
Background: This systematic review was aimed to estimate hepatitis C virus (HCV) seroprevalence and burden in disease in WHO South East Asia Region (SEAR).
Methods: Electronic databases (PubMed, Scopus, Embase, and Google Scholar) and websites of non-indexed national medical journals, government and international health agencies were searched to identify English language literature published between 1991 and June 2020. We selected the studies reporting HCV seroprevalence in asymptomatic general (low-risk) and high-risk adult populations, that is, persons living with HIV (PLHIV), persons who inject drugs (PWID), sex workers, persons on maintenance hemodialysis (MHD), people in prison, and men sex with men (MSM). Seroprevalence data were combined to estimate weighted pooled prevalence (95% confidence interval) in each group and in each country, using the random-effects model. Estimated pooled seroprevalences were multiplied with estimated populations at risk to estimate the overall HCV burden.
Results: The analysis included 538 studies (35 Bangladesh, 6 Bhutan, 2 DPR Korea, 323 India, 43 Indonesia, 2 Maldives, 18 Myanmar, 29 Nepal, 11 Sri Lanka, 67 Thailand, and 2 Timor-Leste). In SEAR, the weighted pooled anti-HCV seroprevalence was estimated as 0.84% (0.56-1.12) in low-risk population and 13.67% (10.95-16.40) in PLHIV, 51.44% (43.67-59.20) in PWID, 25.80% (20.34-32.09) in MHD, 8.39% (5.84-11.51) in prison inmates, 2.69% (1.43-4.13) in people with high-risk sex behavior, and 11.43% (8.61-14.74) in MSM. The total HCV burden in low-risk and high-risk populations in SEAR countries was estimated as 12.45 million and 1.65 million, respectively.
Conclusion: Our estimates of HCV seroprevalence and burden should help the respective countries in planning their HCV elimination strategies.
Keywords: Hemodialysis; Hepatitis C virus; South East Asia region; disease burden; hepatocellular carcinoma; high risk behavior; people living with HIV; people who inject drugs; prison inmates; transfusion transmitted infections.
© 2022 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Similar articles
-
Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.Lancet Glob Health. 2017 Dec;5(12):e1192-e1207. doi: 10.1016/S2214-109X(17)30375-3. Epub 2017 Oct 23. Lancet Glob Health. 2017. PMID: 29074409 Free PMC article.
-
Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups.BMC Infect Dis. 2018 Feb 12;18(1):79. doi: 10.1186/s12879-018-2988-x. BMC Infect Dis. 2018. PMID: 29433454 Free PMC article.
-
Prevalence and Disease Burden of HCV Coinfection in HIV Cohorts in the Asia Pacific Region: A Systematic Review and Meta-Analysis.AIDS Rev. 2016 Apr-Jun;18(2):68-80. AIDS Rev. 2016. PMID: 27196354
-
Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review.Lancet Glob Health. 2023 Dec;11(12):e1885-e1898. doi: 10.1016/S2214-109X(23)00461-8. Lancet Glob Health. 2023. PMID: 37973339
-
Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis.BMC Infect Dis. 2016 Sep 5;16(1):471. doi: 10.1186/s12879-016-1807-5. BMC Infect Dis. 2016. PMID: 27595855 Free PMC article.
Cited by
-
Prevalence of hepatitis B and C viruses among migrant workers in Qatar.Sci Rep. 2024 May 17;14(1):11275. doi: 10.1038/s41598-024-61725-9. Sci Rep. 2024. PMID: 38760415 Free PMC article.
-
Decentralised same day test and treatment of hepatitis C levering existing peer support networks among men who inject drugs: feasibility and effectiveness.Harm Reduct J. 2024 May 20;21(1):98. doi: 10.1186/s12954-024-01001-1. Harm Reduct J. 2024. PMID: 38769517 Free PMC article.
-
Who to Screen for Hepatitis C: That is the Question.J Clin Exp Hepatol. 2022 Nov-Dec;12(6):1406-1407. doi: 10.1016/j.jceh.2022.10.004. Epub 2022 Oct 27. J Clin Exp Hepatol. 2022. PMID: 36340301 Free PMC article. No abstract available.
-
Integrated Behavioral and Biological Surveillance Among People Living With HIV Visiting the Antiretroviral Therapy Centers in India: Protocol for a Cross-Sectional Surveillance.JMIR Res Protoc. 2025 May 21;14:e58252. doi: 10.2196/58252. JMIR Res Protoc. 2025. PMID: 40397957 Free PMC article.
-
Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).PLoS One. 2023 May 18;18(5):e0285725. doi: 10.1371/journal.pone.0285725. eCollection 2023. PLoS One. 2023. PMID: 37200346 Free PMC article.
References
-
- Global Health Estimates 2019: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2019. Geneva, World Health Organization; 2020. Available from https://www.who.int/data/gho/data/themes/mortality-and-global-health-est.... Accessed on 6 February 2022.
-
- Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014; 348: g3308. https://doi.org/10.1136/bmj.g3308
-
- Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014; 312: 631-640. https://doi.org/10.1001/jama.2014.7085
-
- AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed on August 2, 2021.
-
- World Health Organization 2016. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. World Health Organization. Available from https://apps.who.int/iris/handle/10665/246177. Accessed on 6 February 2022.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical